Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...
Drugmaker GSK and U.S. biotechnology company AnaptysBio started litigation against one another, with each saying the other party breached a licensing agreement for cancer treatment Jemperli. Tesaro, a ...
Some four years into Jemperli’s commercial life span, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. Tesaro has filed a lawsuit ...
GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering. Flagship’s Profound Therapeutics and Quotient ...
GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results